Stock 300966 HUBEI GOTO BIOPHARM CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hubei Goto Biopharm Co.,Ltd.

Equities

300966

CNE100004K94

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-05-21 EDT 		5-day change 1st Jan Change
19.65 CNY +2.29% Intraday chart for Hubei Goto Biopharm Co.,Ltd. -4.61% -14.45%
04-26 Hubei Goto Biopharm Co.,Ltd. Proposes Final Cash Dividend for 2023 CI
04-25 Hubei Goto Biopharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 4,729 3,112 2,648
Enterprise Value (EV) 1 4,680 3,429 3,252
P/E ratio 55.4 x 77.5 x 115 x
Yield 0.33% - 0.07%
Capitalization / Revenue 8 x 5.15 x 4.68 x
EV / Revenue 7.92 x 5.67 x 5.74 x
EV / EBITDA 53.9 x 49.8 x 60.7 x
EV / FCF -82 x -8.5 x 293 x
FCF Yield -1.22% -11.8% 0.34%
Price to Book 5.86 x 3.35 x 2.78 x
Nbr of stocks (in thousands) 115,277 115,277 115,278
Reference price 2 41.02 27.00 22.97
Announcement Date 22-04-21 23-04-20 24-04-26
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 464.8 468.1 590.9 604.6 566.4
EBITDA 1 95.68 82.58 86.76 68.9 53.55
EBIT 1 78.64 61.39 64.48 44.6 27.08
Operating Margin 16.92% 13.12% 10.91% 7.38% 4.78%
Earnings before Tax (EBT) 1 82.81 60.24 86.12 38.51 19.12
Net income 1 73 53.29 78.33 40.19 23.01
Net margin 15.7% 11.38% 13.26% 6.65% 4.06%
EPS 2 0.8500 0.6200 0.7400 0.3486 0.2000
Free Cash Flow 1 -23.8 -97.79 -57.11 -403.6 11.08
FCF margin -5.12% -20.89% -9.66% -66.76% 1.96%
FCF Conversion (EBITDA) - - - - 20.7%
FCF Conversion (Net income) - - - - 48.18%
Dividend per Share - - 0.1360 - 0.0160
Announcement Date 21-04-28 21-04-28 22-04-21 23-04-20 24-04-26
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 49.2 121 - 317 604
Net Cash position 1 - - 48.5 - -
Leverage (Debt/EBITDA) 0.5139 x 1.46 x - 4.599 x 11.27 x
Free Cash Flow 1 -23.8 -97.8 -57.1 -404 11.1
ROE (net income / shareholders' equity) 16.4% 10.4% 11.4% 4.37% 2.12%
ROA (Net income/ Total Assets) 6.86% 4.73% 4% 1.7% 0.75%
Assets 1 1,064 1,126 1,959 2,364 3,070
Book Value Per Share 2 5.580 6.200 7.000 8.050 8.260
Cash Flow per Share 2 1.500 0.3400 1.820 3.800 1.580
Capex 1 33.3 18.6 90.9 408 409
Capex / Sales 7.16% 3.97% 15.39% 67.48% 72.26%
Announcement Date 21-04-28 21-04-28 22-04-21 23-04-20 24-04-26
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
HUBEI GOTO BIOPHARM CO.,LTD. Stock Hubei Goto Biopharm Co.,Ltd.
-14.45% 313M
CSL LIMITED Stock CSL Limited
-1.62% 89.22B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.24% 40.49B
BIOGEN INC. Stock Biogen Inc.
-12.97% 32.79B
UCB Stock UCB
+63.43% 26.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-20.71% 14.52B
INCYTE CORPORATION Stock Incyte Corporation
-7.31% 13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.60% 11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.64% 11.5B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.47% 8.82B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 300966 Stock
  4. Financials Hubei Goto Biopharm Co.,Ltd.